E-Prescribing Standards Should Limit Commercial Information, Sen. Grassley Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Electronic Rx systems should prevent drug marketing information from influencing physicians’ prescription choices, the Senate Finance Committee chair says in letter to National Committee on Vital & Health Statistics. Pfizer, J&J agree that process should be “neutral and unbiased.”